



MINISTRY OF HEALTH
1448 NICOSIA

MECC JOINT REGISTRATION PROJECT

Cyprus Cancer Registry (CyCR)

Progress Report for 2011

(Data 2006-2008)

Prepared by: Dr. Pavlos Pavlou
Anna Demetriou
Christiana Soteriou

*Health Monitoring Unit
Ministry of Health
1 Prodr mou Street & 17 Chilonos Street
1448 Lefkosia
Cyprus*

Tel.: +357 22 605457

Fax: +357 22 772238

Website: <http://www.moh.gov.cy>

Data accessed 21st September 2012

Documents:

CyCR_Progress Report 2011_v14.docm

[CANREG_18.xlsm](#)

[CHILDHOOD_INCIDENCE_01.xlsm](#)

[Childhood Cancer.xlsm.lnk](#)

[CyCR FREQUENCY TABLES 2012-09-20.doc](#)

Contents

a) Hiring of new staff.....	3
b) Purchasing of new equipment	3
c) Training.....	3
d) Data collection	3
CyCR Table i. Sources examined for casefinding and abstraction, 2006-2008.	6
CyCR Table ii. Cases abstracted from various sources by type of institution.	6
CyCR Table iii. Cases by healthcare sector by year, 2006-2008.....	7
CyCR Table iv. Cases by district of main abstracting facility by year, 2006-2008	8
CyCR Table v. Cases abstracted from various sources, 2006-2008.....	9
CyCR Table vi. Number and % of cases by basis of diagnosis by year, 2001-2008	10
CyCR Table vii. Percentage of cases by basis of diagnosis by year 1998-2008.....	11
CyCR Table viii. Number and Percentage of DCO cases by IARC group, 2006-2008.....	12
e) Changes in the cancer statistical form.....	13
f) Computer database management	13
g) MECC standardized tables	15
MECC Table 1. Revised Estimated Number of persons living in Cyprus in 2006-2008.....	16
MECC Table 2. Number of new cases of cancer by IARC group, and sex, 2007-2008	17
MECC Table 3. Six most common male cancers in 2008	18
MECC Table 4. Six most common female cancers in 2008	19
MECC Table 5. World Age Standardized Incidence rates by year, by sex, by IARC group.....	20
MECC Table 6. Annual Age Specific Incidence Rates of Prostate cancer, 2008.....	21
MECC Table 7. Annual Age Specific Incidence Rates of Bladder cancer, 2008.....	22
MECC Table 8. Annual Age Specific Incidence Rates of Tr., Br. & Lung cancer, 2008	23
MECC Table 9. Annual Age Specific Incidence Rates of Colon cancer, 2008	24
MECC Table 10. Annual Age Specific Incidence Rates of Rectal cancer, 2008.....	25
MECC Table 11. Annual Age Specific Incidence Rates of Non-Hodgkin Lymphoma, 2008	26
MECC Table 12. Annual Age Specific Incidence Rates of Breast cancer, 2008	27
MECC Table 13. Annual Age Specific Incidence Rates of Corpus Uteri cancer, 2008	28
MECC Table 14. Annual Age Specific Incidence Rates of Stomach cancer, 2008.....	29
MECC Table 15. Annual Age Specific Incidence Rates of Thyroid cancer, 2008	30
Childhood Cancer	31
MECC Table 16. Female childhood cancers, 0-14 yrs, 2006-2008	32
MECC Table 17. Male childhood cancers, 0-14 yrs, 2006-2008	33
h) Notifiability of cancer in the country	34
i) Linking up with death certificates	34
j) Local activities.....	34
k) Problems.....	35
APPENDIX I. CyCR Cancer Registration Form	38

APPENDIX II. CanReg4 Frequencies 1998-2012	41
Number of cases by year by Record status / Sex.....	41
Number of cases by year by Basis of Diagnosis.....	41
Number of cases by year by Residential Status.....	41
Number of cases by year by Ethnicity	42
Number of cases by year by Sex	42
Number of cases by year by Summary Stage	42
Number of cases by year by Grade/Differentiation	42
Number of cases by year by Laterality	42
Number of cases by year by ICD-10 group	43
Number of cases by year by Cause of death	45
Number of cases by year by Vital Status	45
Number of cases by year by Month of incidence	45
Number of cases by year by Cancer Therapy	45
Number of cases by year by Cancer Surgery	45
Number of cases by year by Radiotherapy.....	46
Number of cases by year by Chemotherapy	46
Number of cases by year by Hormone therapy.....	46
Number of cases by year by Immunotherapy	46
Number of cases by year by Other therapy.....	46
Number of cases by year by Topography	47
APPENDIX III. Trends in WASR 1998-2008 (Revised Cy Populations 2011)	49
Figure 1. CyCR: Trends in WASR, All but C44	49
Figure 2. CyCR: Trends in WASR, C16 Stomach	49
Figure 3. CyCR: Trends in WASR, C18-20 Colorectal.....	50
Figure 4. CyCR: Trends in WASR, C33-C34 Tr., Br., Lung.....	50
Figure 5. CyCR: Trends in WASR, C50 Breast	51
Figure 6. CyCR: Trends in WASR, C53 Cervix uteri.....	51
Figure 7. CyCR: Trends in WASR, C54 Corpus Uteri	52
Figure 8. CyCR: Trends in WASR, C56 Ovary	52
Figure 9. CyCR: Trends in WASR, C61 Prostate.....	53
Figure 10. CyCR: Trends in WASR, C62 Testis	53
Figure 11. CyCR: Trends in WASR, C67 Bladder	54
Figure 12. CyCR: Trends in WASR, C70-C72 Brain & NS.....	54
Figure 13. CyCR: Trends in WASR, C73 Thyroid	55
Figure 14. CyCR: Trends in WASR, C81 Hodgkin disease	56
Figure 15. CyCR: Trends in WASR, C82-C85; C96 NHL	56
Figure 16. CyCR: Trends in WASR, C91 Lymphoid Leukemia	57
Figure 17. CyCR: Trends in WASR, C92-C94 Myeloid Leukemia	57
Figure 18. CyCR: Trends in WASR, O&U Other & Unspecified.....	58
APPENDIX IV. Childhood Cancer by ICC 2006-2008	59

CYPRUS CANCER REGISTRY (CyCR)

Progress Report 2011

This Report describes the main activities of the Cyprus Cancer Registry (CyCR) during 2011. In this year, we completed data entry and quality checks for cancer cases incident in 2008. The Report is in line with the structure proposed by MECC. We have included a number of additional tables and graphs that may be useful to other readers.

a) Hiring of new staff

There were no staff changes since the last report of 2010.

Registry Staff

- Dr. Pavlos Pavlou, Director of Operations and MECC Principal Investigator (part-time).
- Ms. Christiana Soteriou, Office Cancer Registrar (full-time).
- Ms. Koula Lysandridou, Itinerary Cancer Registrar (full-time).
- Ms. Maria Kleridou, Itinerary Cancer Registrar (full-time).
- Ms. Anna Demetriou, Statistician (part-time).
- Mr. Xenios Anastassiades, Information Technology Officer (part-time).

b) Purchasing of new equipment

A new desktop computer was purchased in 2011, by the Department of Information Technology Services for the Health Monitoring Unit. This is being used by the office cancer registrar.

c) Training

There was no formal training for the staff in 2011.

d) Data collection

We carried on with the usual casefinding, abstraction, resolution and deletion procedures as in previous years. We continued our cooperation with the Bank of Cyprus Oncology Centre in exporting and importing **electronic data** for 2010, 2011 and 2012. Most of the demographic fields and some clinical fields, including first **radiotherapy** and date, were imported successfully. Electronic imports involved BOCOC cases admitted up to March 2011.

BOCOC staff prepared Excel files according to a specified data structure. These were imported into Access. We cleaned the data and converted some of the text fields to coded format. The spelling of names in BOCOC files, now conforms with the Romanic standard of transliteration that is used by CanReg4. This improves the ability of our system to identify duplicate persons. Data are processed in Access and then exported to a text file suitable for importing. We use the import facility of CanReg4.

The electronic case records are imported as '**pending**'. They are checked and 'confirmed', case by case by the cancer registrars. Whenever necessary, the principal investigator is consulted. This data import procedure has saved a lot of typing and has also helped to avoid typing mistakes.

Despite our efforts, we were not able to export/import **chemotherapy, hormone therapy and immunotherapy** data from the BOCOC database during 2011. We continue our efforts, in cooperation with the BOCOC staff, to make this possible in 2012.

First surgery with dates is not systematically recorded in the clinical notes or the electronic files of BOCOC. These data were abstracted from all available paper clinical records as best we could.

The **main benefit** of electronic data transfer is improvement in completeness and quality of data. It does not seem to have made a major improvement in speed of cancer registration. Most of the delays occur during casefinding procedures and while the office registrar reads the entries in histology reports and other clinical records in order to assign the correct topography, morphology, summary staging, differentiation, tumour sequence and date codes. This is because most of BOCOC's tumour data, with exception of diagnosis and TNM staging, are not coded. Some are recorded electronically as text. Furthermore, BOCOC's diagnosis codes are based on ICD-10. There is no separate coding for topography or morphology. It is therefore, not possible to do direct electronic transfer of diagnoses with ICD-O-3 topography and morphology codes. We import them as text and the office registrar assigns the appropriate ICD-O-3 codes manually. The same applies to staging and grade/differentiation data.

We have not yet been able to export/ import data from the **public hospital discharge files**. In 2011 we had the usual difficulties in getting the data we need.

We continued importing **Death Certificate Notified** cases. They were imported from the electronic Causes of Death Database that was created in 2004 by the Health Monitoring Unit. Most of the death data before 2004, are only available in electronic files obtained from the Ministry of Interior. Original copies of these old death certificates are not easily available. Therefore, the accuracy of certification and coding of deaths before 2004 cannot be assessed.

In 2011 we imported all death records having cancer as the underlying cause of death or cancer mentioned as one of the multiple causes. The death records were imported as **pending**. They were individually checked and confirmed by the office registrar. This procedure has made a significant improvement in the completeness of cancer registration but the percentage of DCO cases for 2004-2008 is quite high, at around 10% of all incident cases. The cancers with the highest percentage of DCO cases are shown in CyCR Table viii, page 12. **Follow-back** for these cases is time consuming, and inefficient.

By using the dates of death for non cancer deaths we have improved the recording of follow-up data that are necessary for calculating cancer survival. Death records were imported irrespective of whether they had a matching national ID in the Cancer Registry. Any person duplicates were identified by using the 'person check' facility of CanReg4.

The process of recording **resident addresses** in coded format, that were introduced in 2009, were sustained and further consolidated in 2011. We now use a coded list of all the streets in the government controlled areas of Cyprus. This list is included in our CanReg4 dictionary. Updates, supplied by the Post Office at 3 monthly intervals, are used to update our dictionary. This innovation has made the recording of residence much more accurate and consistent. The original address text data are kept in the data base.

The field for **occupation** was modified to facilitate data entry. It is now possible to use the new International Standard Classification of Occupations (ISCO-08). The completeness of the occupation field is quite low, at around 40-50%, mainly because it is not always recorded in the clinical notes. There is also a significant proportion of unspecified occupations such as 'housewife' or 'retired'. As a result, the usefulness of this field is in doubt. However, one cannot exclude the possibility of using it for research in the future.

Some of the fields that were previously recorded as text, such as the histologist fields, have been converted to coded fields.

The following tables show some useful statistics for the period 2006-2008.


CyCR Table i. Sources examined for casefinding and abstraction, 2006-2008.

Type of Source	Source Names	Public Sector	Private Sector
Histopathology Laboratories	Lefkosia GH, Private Laboratories	1	5
Cytology Department	Lefkosia GH	1	
Bone Marrow Registry	Lefkosia Makarios Hospital	1	
Pediatric Oncology Dep/ts	Lefkosia Makarios Hospital	1	
Hematology Departments	Lefkosia GH, Lemesos GH	2	
Oncology Departments	Lefkosia GH, Lemesos GH and BOCOC (Hospital Records)	2	1
Surgical Theatre Logbooks	Lefkosia GH and Lemesos GH (General Surgery)	2	
Private Doctors	About 110 private doctors have notified cancer cases.		110

CyCR Table ii. Cases abstracted from various sources by type of institution.

Record status: Confirmed
 Behaviour: Malignant
 Population base: Government controlled areas


Type of Institution	2006		2007		2008		2006-2008	
	Count	%	Count	%	Count	%	Count	%
Hospital	2143	87%	2343	86%	2462	87%	6948	87%
Clinic	77	3%	96	4%	90	3%	263	3%
Hospice	10	0%	10	0%	12	0%	32	0%
Not stated	227	9%	269	10%	280	10%	776	10%
Total	2457	100%	2718	100%	2844	100%	8019	100%



CyCR Table iii. Cases by healthcare sector by year, 2006-2008

Record status: Confirmed
 Behaviour: Malignant
 Population base: Government controlled areas


Healthcare Sector	2006		2007		2008		2006-2008	
	Count	%	Count	%	Count	%	Count	%
Private	1570	64%	1762	65%	1751	62%	5083	63%
Public	708	29%	741	27%	864	30%	2313	29%
Not stated	179	7%	215	8%	229	8%	623	8%
Total	2457	100%	2718	100%	2844	100%	8019	100%



CyCR Table iv. Cases by district of main abstracting facility by year, 2006-2008

Record status: Confirmed
 Behaviour: Malignant
 Population base: Government controlled areas


District of facility	2006		2007		2008		2006-2008	
	Count	%	Count	%	Count	%	Count	%
Lefkosia	1773	72%	1940	71%	1979	70%	5692	71%
Lemesos	301	12%	331	12%	377	13%	1009	13%
Larnaka	77	3%	68	3%	83	3%	228	3%
Pafos	72	3%	104	4%	111	4%	287	4%
Ammochostos	7	0%	6	0%	14	0%	27	0%
Not stated	227	9%	269	10%	280	10%	776	10%
Total	2457	100%	2718	100%	2844	100%	8019	100%



CyCR Table v. Cases abstracted from various sources, 2006-2008


Record status Confirmed
 Behaviour All cases, malignant and in-situ
 Population base All areas in Cyprus and abroad

Short name of Facility	2006		2007		2008		2006-2008	
	Count	%	Count	%	Count	%	Count	%
Bank of Cyprus Oncology Centre	1436	54.3%	1634	55.4%	1616	52.9%	4686	54.2%
Lefkosia General Hospital	334	12.6%	369	12.5%	438	14.3%	1141	13.2%
Lemesos General Hospital	247	9.3%	257	8.7%	288	9.4%	792	9.2%
Makario Nosokomio Lefkosia	51	1.9%	30	1.0%	28	0.9%	109	1.3%
Larnaka General Hospital	72	2.7%	71	2.4%	82	2.7%	225	2.6%
Lemesos Private Hospital 1	44	1.7%	57	1.9%	71	2.3%	172	2.0%
Pafos General Hospital	43	1.6%	50	1.7%	60	2.0%	153	1.8%
Lefkosia Private Hospital 2	11	0.4%	12	0.4%	15	0.5%	38	0.4%
Lefkosia Private Clinic 1	4	0.2%	1	0.0%			5	0.1%
Lefkosia Private Clinic 3	11	0.4%	7	0.2%	11	0.4%	29	0.3%
Pafos Private Clinic 01	10	0.4%	7	0.2%	9	0.3%	26	0.3%
Pafos Private Clinic 02	13	0.5%	40	1.4%	20	0.7%	73	0.8%
Lemesos Private Clinic 1	5	0.2%	11	0.4%	10	0.3%	26	0.3%
Arodafnousa	10	0.4%	10	0.3%	12	0.4%	32	0.4%
Ammochostos Private Clinic 1	5	0.2%	5	0.2%	6	0.2%	16	0.2%
Pafos Private Clinic 03	11	0.4%	10	0.3%	8	0.3%	29	0.3%
Larnaka Private Clinic 2	5	0.2%	2	0.1%			7	0.1%
Kyperounta Hospital	7	0.3%	9	0.3%	4	0.1%	20	0.2%
Larnaka Private Clinic 1	6	0.2%	3	0.1%	5	0.2%	14	0.2%
Larnaka Private Clinic 3	2	0.1%					2	0.0%
Lefkosia Private Clinic 17	1	0.0%	3	0.1%			4	0.0%
Lefkosia Private Clinic 4	3	0.1%	2	0.1%	1	0.0%	6	0.1%
Lefkosia Private Clinic 8	1	0.0%	1	0.0%	2	0.1%	4	0.0%
Lefkosia Private Hospital 3	16	0.6%	9	0.3%	6	0.2%	31	0.4%
Lefkosia Private Hospital 4	18	0.7%	23	0.8%	24	0.8%	65	0.8%
Lemesos Private Clinic 10	1	0.0%	1	0.0%	1	0.0%	3	0.0%
Lemesos Private Clinic 12			2	0.1%			2	0.0%
Lemesos Private Clinic 2			2	0.1%			2	0.0%
Lemesos Private Clinic 23	1	0.0%			1	0.0%	2	0.0%
Lemesos Private Clinic 24			1	0.0%			1	0.0%
Lemesos Private Clinic 25	7	0.3%	5	0.2%	14	0.5%	26	0.3%
Lemesos Private Clinic 27			1	0.0%	1	0.0%	2	0.0%
Lemesos Private Clinic 3	1	0.0%	2	0.1%			3	0.0%
Lemesos Private Clinic 40	1	0.0%					1	0.0%
Lemesos Private Clinic 42	1	0.0%	1	0.0%			2	0.0%
Lemesos Private Clinic 5	2	0.1%					2	0.0%
Lemesos Private Clinic 7	1	0.0%	1	0.0%	1	0.0%	3	0.0%
Lemesos Private Clinic 8	1	0.0%			1	0.0%	2	0.0%
Pafos Private Clinic 04	2	0.1%	2	0.1%	1	0.0%	5	0.1%
Pafos Private Clinic 05	2	0.1%	4	0.1%	1	0.0%	7	0.1%
Pafos Private Clinic 06			1	0.0%			1	0.0%
Pafos Private Clinic 08	2	0.1%	3	0.1%	15	0.5%	20	0.2%
Pafos Private Clinic 10					1	0.0%	1	0.0%
Pafos Private Clinic 14					1	0.0%	1	0.0%
Pafos Private Clinic 16	4	0.2%	2	0.1%			6	0.1%
Paralimni Hospital	5	0.2%	3	0.1%	8	0.3%	16	0.2%
Paraskevaidio Transplant Centre	3	0.1%	4	0.1%			7	0.1%
UNKNOWN	246	9.3%	289	9.8%	291	9.5%	826	9.6%
Total	2646	100%	2947	100%	3053	100%	8646	100%





CyCR Table vi. Number and % of cases by basis of diagnosis by year, 2001-2008

BasisG	Year								
	2001	2002	2003	2004	2005	2006	2007	2008	Total
DCO	146	167	153	235	246	236	286	276	1745
Microscopic	1716	1790	1949	2097	2123	2170	2398	2538	16781
Non Microscopic	35	66	33	32	31	34	26	25	282
Unknown	12	22	21	12	15	17	8	5	112
Total	1909	2045	2156	2376	2415	2457	2718	2844	18920



CyCR Table vii. Percentage of cases by basis of diagnosis by year 1998-2008

Basis of diagnosis	Year								
	2001	2002	2003	2004	2005	2006	2007	2008	Total
DCO	8%	8%	7%	10%	10%	10%	11%	10%	9%
Microscopic	90%	88%	90%	88%	88%	88%	88%	89%	89%
Non Microscopic	2%	3%	2%	1%	1%	1%	1%	1%	1%
Unknown	1%	1%	1%	1%	1%	1%	0%	0%	1%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%



CyCR Table viii. Number and Percentage of DCO cases by IARC group, 2006-2008

Sex Record status Population base Behaviour Ag(85+) Years	All Confirmed Government controlled Malignant All ages 2006-2008			
Count of RegiNo IARCCRT	Number of All cases	Number of DCO	Percentage DCO	
C00 Lip	22	1	4.5%	
C01-C02 Tongue	17	1	5.9%	
C03-C06 Mouth	26			
C07-C08 Salivary glands	19	1	5.3%	
C09 Tonsil	6			
C10 Other Oropharynx	3			
C11 Nasopharynx	13			
C12-C13 Hypopharynx	2			
C14 Pharynx unspec.				
C15 Oesophagus	37	10	27.0%	
C16 Stomach	240	19	7.9%	
C17 Small intestine	12	1	8.3%	
C18-C20 Colorectal	958	67	7.0%	
C21 Anus	20			
C22 Liver	122	61	50.0%	
C23-C24 Gallbladder etc.	66	12	18.2%	
C25 Pancreas	173	49	28.3%	
C30-C31 Nose, sinuses etc.	9			
C32 Larynx	79	7	8.9%	
C33-C34 Tr., Br., Lung	646	91	14.1%	
C37-C38 Other Thoracic organs	21	1	4.8%	
C40-C41 Bone	19			
C43 Melanoma of Skin	155	4	2.6%	
C44 Other Skin				
C45 Mesothelioma	29	2	6.9%	
C46 Kaposi sarcoma	8			
C47;C49 Connective, Soft tissue	78	1	1.3%	
C50 Breast	1348	53	3.9%	
C51 Vulva	22			
C52 Vagina	3			
C53 Cervix Uteri	78	1	1.3%	
C54 Corpus Uteri	218	4	1.8%	
C55 Uterus unspec.	20	10	50.0%	
C56 Ovary	134	16	11.9%	
C57 Other Female Genital	9	1	11.1%	
C58 Placenta				
C60 Penis	23			
C61 Prostate	1074	85	7.9%	
C62 Testis	68	1	1.5%	
C63 Other male genital				
C64 Kidney	113	10	8.8%	
C65 Renal Pelvis	6			
C66 Ureter	5			
C67 Bladder	432	23	5.3%	
C68 Other Urinary organs	5			
C69 Eye	8			
C70-C72 Brain, & NS	159	35	22.0%	
C73 Thyroid	334	6	1.8%	
C74 Adrenal gland	9	1	11.1%	
C75 Other Endocrine	1	1	100.0%	
C81 Hodgkin disease	76			
C82-C85;C96 NHL	302	16	5.3%	
C88 Immunoproliferative dis	1	1	100.0%	
C90 Multiple Myeloma	124	18	14.5%	
C91 Lymphoid Leukaemia	122			
C92-C94 Myeloid Leukaemia	104			
C95 Leukaemia unspec.	51	48	94.1%	
MDS Myelodysplastic syndr	29			
MPD Myeloproliferative dis	41			
O&U Other & Unspecified	320	140	43.8%	
Total	8019	798	10.0%	

Main problems in collecting the data

- Incomplete Hospital Records.
- Incomplete Information Technology System in Government Hospitals.
- Inappropriate Storage of records in the hospitals (inaccessible or mislaid).
- Lack of Notification Law.

e) Changes in the cancer statistical form

The Cancer Registration Form designed in 2009 and slightly modified in 2010 was used during 2011. The form is shown in Appendix I.

f) Computer database management

The changes in the computer programme **CanReg4** made in 2009 have remained stable with a few minor modifications. New fields were added (particularly on treatment data), other fields were modified. No fields were deleted. The current structure contains some data fields that are now considered to be redundant. These are maintained on purpose, in order to allow some time to ensure new data fields are correctly used.

The procedures of **electronic data uploading** from Excel files obtained from BOCOC are being followed as in the previous year. Importing of electronic data mainly involves the demographic data. Morphology data are not available and Topography data do not always conform to ICD-O-3. All such data uploaded in the Cancer Registry are entered as pending. They are checked in the usual manner by the Cancer Registrars before being confirmed.

Back-up procedures follow a rotation scheme of daily, weekly and monthly full back-ups using the CanReg4 back-up facility.

Text files of the registry database are exported to the Data Warehouse of the Health Monitoring Unit where they are stored for use in data analysis. The data warehouse also routinely performs quality checks. Any errors detected are notified to the cancer registrar for the necessary manual checks and corrections.

In 2011 we repeated the **quality checks** we introduced in the previous year. These included IARC tools, DEP edits and the computer edits recommended in the SEER Summary Staging Manual. We have also used our own computer checks in the Health Monitoring Unit Data Warehouse.


Data analysis and reporting is done by the HMU statistician and the PI using various tools such as IBM DB2, Microsoft Access, Excel, SPSS, Word, Powerpoint etc.

g) MECC standardized tables

MECC Table 1. Revised Estimated Number of persons living in Cyprus in 2006-2008.

Age	2006			2007			2008		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4	21796	20404	42200	22309	20898	43207	22976	21577	44553
5-9	23096	22144	45240	22704	21434	44138	22442	21237	43679
10-14	28438	27035	55473	27631	26253	53884	26968	25518	52486
15-19	30646	28705	59351	31758	29824	61582	32218	30349	62567
20-24	31455	30370	61825	32533	31596	64129	33645	32825	66470
25-29	29060	29685	58745	30525	31452	61977	32273	33374	65647
30-34	25255	28567	53822	25962	29143	55105	26965	30335	57300
35-39	24364	27853	52217	25279	28972	54251	26197	30316	56513
40-44	26059	28257	54316	25991	28528	54519	25943	28941	54884
45-49	26707	27762	54469	27210	28419	55629	27523	28957	56480
50-54	23331	23617	46948	24092	24454	48546	25055	25541	50596
55-59	22018	22606	44624	22648	23164	45812	23052	23459	46511
60-64	17022	17959	34981	18153	19021	37174	19544	20364	39908
65-69	14704	15733	30437	15062	16104	31166	15372	16451	31823
70-74	10892	12845	23737	11438	13196	24634	12058	13644	25702
75-79	7894	10302	18196	8122	10508	18630	8392	10798	19190
80-84	5135	6961	12096	5279	7169	12448	5454	7449	12903
85+	3642	5597	9239	3762	5740	9502	3849	5869	9718
Total	371514	386402	757916	380458	395875	776333	389926	407004	796930

Source: Statistical Service of Cyprus, Ministry of Finance. Revised on the basis of Census 2001 & 2011.




MECC Table 2. Number of new cases of cancer by IARC group, and sex, 2007-2008

IARCCRT	2007				Total		2008				Total	
	M		F		Total	%	M		F		Total	%
	%	%	%	%								
Basis of diagnosis (All)												
Record status (Confirmed)												
Population base (Government controlled areas)												
Behaviour (Malignant)												
Ag(85+) (All)												
	Year		Sex									
C00 Lip	8	0.6%			8	0.3%	6	0.4%	1	0.1%	7	0.2%
C01-C02 Tongue	1	0.1%	1	0.1%	2	0.1%	7	0.5%	3	0.2%	10	0.4%
C03-C06 Mouth	7	0.5%	4	0.3%	11	0.4%	6	0.4%	4	0.3%	10	0.4%
C07-C08 Salivary glands	3	0.2%	4	0.3%	7	0.3%	3	0.2%	4	0.3%	7	0.2%
C09 Tonsil	2	0.1%	1	0.1%	3	0.1%	1	0.1%	1	0.1%	2	0.1%
C10 Other Oropharynx							2	0.1%			2	0.1%
C11 Nasopharynx	2	0.1%	1	0.1%	3	0.1%	7	0.5%	2	0.1%	9	0.3%
C12-C13 Hypopharynx	1	0.1%	1	0.1%	2	0.1%						
C14 Pharynx unspec.												
C15 Oesophagus	10	0.7%	4	0.3%	14	0.5%	5	0.3%	4	0.3%	9	0.3%
C16 Stomach	49	3.5%	26	1.9%	75	2.8%	51	3.5%	42	3.0%	93	3.3%
C17 Small intestine	2	0.1%	2	0.1%	4	0.1%	2	0.1%	3	0.2%	5	0.2%
C18-C20 Colorectal	180	13.0%	175	13.1%	355	13.1%	179	12.2%	132	9.6%	311	10.9%
C21 Anus	4	0.3%	5	0.4%	9	0.3%	2	0.1%	4	0.3%	6	0.2%
C22 Liver	35	2.5%	16	1.2%	51	1.9%	22	1.5%	11	0.8%	33	1.2%
C23-C24 Gallbladder etc.	13	0.9%	11	0.8%	24	0.9%	8	0.5%	13	0.9%	21	0.7%
C25 Pancreas	35	2.5%	30	2.2%	65	2.4%	30	2.0%	34	2.5%	64	2.3%
C30-C31 Nose, sinuses etc.	2	0.1%	3	0.2%	5	0.2%	1	0.1%			1	0.0%
C32 Larynx	22	1.6%	1	0.1%	23	0.8%	33	2.3%	1	0.1%	34	1.2%
C33-C34 Tr., Br., Lung	163	11.8%	45	3.4%	208	7.7%	184	12.6%	56	4.1%	240	8.4%
C37-C38 Other Thoracic organs	4	0.3%	5	0.4%	9	0.3%	3	0.2%	4	0.3%	7	0.2%
C40-C41 Bone	5	0.4%	2	0.1%	7	0.3%	4	0.3%			4	0.1%
C43 Melanoma of Skin	27	2.0%	29	2.2%	56	2.1%	33	2.3%	33	2.4%	66	2.3%
C44 Other Skin												
C45 Mesothelioma	6	0.4%	1	0.1%	7	0.3%	8	0.5%	1	0.1%	9	0.3%
C46 Kaposi sarcoma	1	0.1%	1	0.1%	2	0.1%	4	0.3%			4	0.1%
C47;C49 Connective, Soft tissue	19	1.4%	8	0.6%	27	1.0%	14	1.0%	17	1.2%	31	1.1%
C50 Breast	5	0.4%	475	35.5%	480	17.7%	7	0.5%	444	32.2%	451	15.9%
C51 Vulva			8	0.6%	8	0.3%			8	0.6%	8	0.3%
C52 Vagina			1	0.1%	1	0.0%						
C53 Cervix Uteri			29	2.2%	29	1.1%			24	1.7%	24	0.8%
C54 Corpus Uteri			67	5.0%	67	2.5%			81	5.9%	81	2.8%
C55 Uterus unspec.			3	0.2%	3	0.1%			9	0.7%	9	0.3%
C56 Ovary			46	3.4%	46	1.7%			54	3.9%	54	1.9%
C57 Other Female Genital			3	0.2%	3	0.1%			4	0.3%	4	0.1%
C58 Placenta												
C60 Penis	6	0.4%			6	0.2%	11	0.8%			11	0.4%
C61 Prostate	353	25.6%			353	13.0%	381	26.0%			381	13.4%
C62 Testis	22	1.6%			22	0.8%	24	1.6%			24	0.8%
C63 Other male genital												
C64 Kidney	18	1.3%	10	0.7%	28	1.0%	28	1.9%	18	1.3%	46	1.6%
C65 Renal Pelvis	1	0.1%	1	0.1%	2	0.1%			2	0.1%	2	0.1%
C66 Ureter	1	0.1%			1	0.0%			1	0.1%	1	0.0%
C67 Bladder	120	8.7%	23	1.7%	143	5.3%	128	8.7%	29	2.1%	157	5.5%
C68 Other Urinary organs	2	0.1%			2	0.1%	1	0.1%			1	0.0%
C69 Eye	1	0.1%	1	0.1%	2	0.1%			2	0.1%	2	0.1%
C70-C72 Brain, & NS	26	1.9%	30	2.2%	56	2.1%	25	1.7%	27	2.0%	52	1.8%
C73 Thyroid	20	1.4%	82	6.1%	102	3.8%	25	1.7%	121	8.8%	146	5.1%
C74 Adrenal gland	1	0.1%	2	0.1%	3	0.1%	3	0.2%			3	0.1%
C75 Other Endocrine			1	0.1%	1	0.0%						
C81 Hodgkin disease	12	0.9%	7	0.5%	19	0.7%	14	1.0%	14	1.0%	28	1.0%
C82-C85;C96 NHL	45	3.3%	45	3.4%	90	3.3%	55	3.8%	54	3.9%	109	3.8%
C88 Immunoproliferative dis	1	0.1%			1	0.0%						
C90 Multiple Myeloma	23	1.7%	25	1.9%	48	1.8%	17	1.2%	27	2.0%	44	1.5%
C91 Lymphoid Leukaemia	28	2.0%	13	1.0%	41	1.5%	26	1.8%	13	0.9%	39	1.4%
C92-C94 Myeloid Leukaemia	23	1.7%	9	0.7%	32	1.2%	26	1.8%	12	0.9%	38	1.3%
C95 Leukaemia unspec.	5	0.4%	11	0.8%	16	0.6%	13	0.9%	6	0.4%	19	0.7%
MDS Myelodysplastic syndr	6	0.4%	3	0.2%	9	0.3%	5	0.3%	3	0.2%	8	0.3%
MPD Myeloproliferative dis	9	0.7%	8	0.6%	17	0.6%	8	0.5%	5	0.4%	13	0.5%
O&U Other & Unspecified	52	3.8%	58	4.3%	110	4.0%	53	3.6%	51	3.7%	104	3.7%
Total	1381	100%	1337	100%	2718	100%	1465	100%	1379	100%	2844	100%

MECC Table 3. Six most common male cancers in 2008

CyCR, 2008: Top Six Male Cancers, % of 1465


ICD-10 group	Cases	%
C61 Prostate	381	26.0%
C33-C34 Tr., Br., Lung	184	12.6%
C18-C20 Colorectal	179	12.2%
C67 Bladder	128	8.7%
C82-C85;C96 NHL	55	3.8%
C16 Stomach	51	3.5%
All others	487	33.2%
Total	1465	100.0%



MECC Table 4. Six most common female cancers in 2008

CyCR, 2008: Top Six Female Cancers, % of 1379

ICD-10 group	Cases	%
C50 Breast	444	32.2%
C18-C20 Colorectal	132	9.6%
C73 Thyroid	121	8.8%
C54 Corpus Uteri	81	5.9%
C33-C34 Tr., Br., Lung	56	4.1%
C82-C85;C96 NHL	54	3.9%
All others	491	35.6%
Total	1379	100.0%




MECC Table 5. World Age Standardized Incidence rates by year, by sex, by IARC group.

WASR IARCCRT	2006		2007		2008	
	Male	Female	Male	Female	Male	Female
C00 Lip	1.0	0.1	1.6		1.0	0.2
C01-C02 Tongue	0.5	0.6	0.2	0.2	1.2	0.4
C03-C06 Mouth	0.8	0.1	1.4	0.8	1.1	0.5
C07-C08 Salivary glands	0.9	0.1	0.4	0.5	0.6	0.5
C09 Tonsil	0.2		0.4	0.2	0.2	0.2
C10 Other Oropharynx	0.2				0.3	
C11 Nasopharynx	0.2		0.4	0.2	1.8	0.4
C12-C13 Hypopharynx			0.2	0.1		
C14 Pharynx unspec.						
C15 Oesophagus	2.3	0.4	1.9	0.5	0.8	0.4
C16 Stomach	8.3	4.0	9.0	3.8	8.2	5.5
C17 Small intestine	0.2	0.2	0.4	0.3	0.4	0.5
C18-C20 Colorectal	28.9	21.1	29.9	25.1	30.0	19.8
C21 Anus	0.2	0.8	0.8	0.9	0.4	0.5
C22 Liver	4.1	1.3	5.5	2.1	3.5	1.4
C23-C24 Gallbladder etc.	1.7	1.4	2.0	1.4	1.2	1.7
C25 Pancreas	4.1	3.2	6.4	3.9	4.9	4.3
C30-C31 Nose, sinuses etc.	0.5	0.2	0.2	0.3	0.1	
C32 Larynx	3.6	0.5	4.3	0.2	5.8	0.2
C33-C34 Tr., Br., Lung	25.5	9.4	28.5	8.1	30.8	8.6
C37-C38 Other Thoracic organs	0.6	0.4	0.8	0.8	0.5	0.7
C40-C41 Bone	1.7	0.5	1.4	0.6	1.2	
C43 Melanoma of Skin	2.5	3.3	5.2	5.1	5.8	5.7
C44 Other Skin						
C45 Mesothelioma	1.9	0.4	0.9	0.2	1.4	
C46 Kaposi sarcoma	0.5		0.1		0.7	
C47;C49 Connective, Soft tissue	2.6	1.5	3.9	1.4	2.5	3.3
C50 Breast	1.3	76.2	1.0	84.9	1.1	76.6
C51 Vulva		0.7		1.1		1.1
C52 Vagina		0.3		0.2		
C53 Cervix Uteri		4.5		5.1		4.7
C54 Corpus Uteri		12.5		10.3		13.6
C55 Uterus unspec.		1.0		0.5		1.2
C56 Ovary		5.8		8.0		8.2
C57 Other Female Genital		0.4		0.5		0.7
C58 Placenta						
C60 Penis	1.3		1.1		1.8	
C61 Prostate	58.2		60.1		61.6	
C62 Testis	5.6		5.3		5.7	
C63 Other male genital						
C64 Kidney	5.5	2.0	3.6	1.8	5.0	3.0
C65 Renal Pelvis	0.3		0.1	0.2		0.3
C66 Ureter	0.6		0.2			0.2
C67 Bladder	20.2	2.2	19.6	3.6	20.8	3.9
C68 Other Urinary organs	0.4		0.2		0.1	
C69 Eye	0.5	0.3	0.1	0.1		0.2
C70-C72 Brain, & NS	6.1	4.6	5.5	5.4	4.4	4.6
C73 Thyroid	4.4	14.5	4.3	17.4	5.3	24.6
C74 Adrenal gland		1.1	0.2	0.8	0.6	
C75 Other Endocrine				0.1		
C81 Hodgkin disease	4.1	3.2	3.0	1.8	3.7	3.3
C82-C85;C96 NHL	11.4	8.0	8.8	7.6	9.9	8.4
C88 Immunoproliferative dis			0.2			
C90 Multiple Myeloma	3.5	2.2	3.9	4.3	2.9	3.9
C91 Lymphoid Leukaemia	4.9	4.5	6.4	2.9	5.9	2.5
C92-C94 Myeloid Leukaemia	4.5	3.2	4.6	2.0	4.5	1.9
C95 Leukaemia unspec.	1.8	0.7	0.7	1.0	1.8	0.6
MDS Myelodysplastic syndr	1.2	0.6	0.8	0.4	0.7	0.4
MPD Myeloproliferative dis	0.7	1.5	1.7	1.4	1.4	0.6
O&U Other & Unspecified	9.9	5.4	9.3	8.5	8.1	6.2
All but NMS	239.5	204.8	246.6	226.5	249.9	225.7


MECC Table 6. Annual Age Specific Incidence Rates of Prostate cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C61 Prostate cancer	
Male	
0-4	
5-9	
10-14	
15-19	
20-24	
25-29	
30-34	
35-39	
40-44	3.9
45-49	14.9
50-54	53.1
55-59	133.3
60-64	324.9
65-69	466.4
70-74	492.6
75-79	744.5
80-84	713.6
85+	931.3
Crude IR	97.7
WASR	61.6




MECC Table 7. Annual Age Specific Incidence Rates of Bladder cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C67 Bladder cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24	3.1	
25-29		
30-34	7.8	
35-39	4.0	
40-44		3.7
45-49	3.8	
50-54	33.8	8.4
55-59	45.9	
60-64	92.0	15.8
65-69	110.1	32.6
70-74	219.3	31.5
75-79	252.1	39.8
80-84	290.9	86.5
85+	137.4	36.6
Crude IR	32.8	7.1
WASR	20.8	3.9




MECC Table 8. Annual Age Specific Incidence Rates of Tr., Br. & Lung cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C33-C34 Tr., Br., Lung cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		3.3
20-24		
25-29		
30-34	7.5	3.3
35-39	3.9	
40-44	19.6	3.5
45-49	11.1	17.3
50-54	48.7	11.7
55-59	61.7	29.8
60-64	192.5	39.3
65-69	145.5	24.3
70-74	269.8	80.6
75-79	218.0	74.1
80-84	428.7	94.0
85+	316.9	
Crude IR	47.2	13.8
WASR	30.8	8.6




MECC Table 9. Annual Age Specific Incidence Rates of Colon cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C18 Colon cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		
25-29	3.2	
30-34		
35-39	4.0	
40-44	8.0	7.0
45-49	26.3	27.9
50-54	20.7	23.7
55-59	31.4	47.4
60-64	90.0	64.5
65-69	114.4	43.0
70-74	154.5	103.7
75-79	172.6	93.6
80-84	151.8	149.3
85+	483.9	189.4
Crude IR	30.5	23.1
WASR	19.9	13.8




MECC Table 10. Annual Age Specific Incidence Rates of Rectal cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C19-C20 Rectum cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		
25-29		
30-34		
35-39	3.9	6.6
40-44		3.5
45-49	7.4	
50-54	24.4	23.5
55-59	30.9	17.1
60-64	41.6	34.4
65-69	46.3	30.4
70-74	109.6	36.6
75-79	72.7	27.8
80-84	74.6	67.1
85+	132.1	
Crude IR	15.4	9.3
WASR	10.1	6.1




MECC Table 11. Annual Age Specific Incidence Rates of Non-Hodgkin Lymphoma, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C82-C85;C96 NHL cancer		
	Male	Female
0-4		
5-9		
10-14		4.1
15-19	3.2	3.4
20-24		3.2
25-29		3.1
30-34	11.3	
35-39	11.7	
40-44	27.5	3.6
45-49	3.7	
50-54	16.3	24.4
55-59	17.7	26.6
60-64	31.3	40.8
65-69	33.1	18.9
70-74	67.6	53.3
75-79	48.5	67.3
80-84	149.4	97.6
85+		53.1
Crude IR	14.1	13.3
WASR	9.9	8.4




MECC Table 12. Annual Age Specific Incidence Rates of Breast cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C50 Breast cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		6.1
25-29		3.0
30-34		29.9
35-39		53.1
40-44		111.3
45-49		180.8
50-54	4.0	224.7
55-59	4.3	236.0
60-64		316.4
65-69	6.5	269.3
70-74	8.3	324.7
75-79	35.7	279.7
80-84		229.8
85+		308.8
Crude IR	1.8	109.1
WASR	1.1	76.6




MECC Table 13. Annual Age Specific Incidence Rates of Corpus Uteri cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C54 Corpus Uteri cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		3.1
25-29		
30-34		
35-39		6.7
40-44		7.0
45-49		21.0
50-54		51.5
55-59		56.1
60-64		44.7
65-69		80.0
70-74		59.4
75-79		56.3
80-84		81.6
85+		17.3
Crude IR		19.9
WASR		13.6




MECC Table 14. Annual Age Specific Incidence Rates of Stomach cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C16 Stomach cancer		
	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		
25-29		3.1
30-34		
35-39		
40-44	3.9	
45-49	3.6	3.6
50-54	16.0	4.1
55-59	21.7	17.9
60-64	25.6	30.9
65-69	45.5	19.1
70-74	82.9	38.5
75-79	59.6	38.9
80-84	110.0	141.0
85+	181.9	89.5
Crude IR	13.1	10.3
WASR	8.2	5.5



MECC Table 15. Annual Age Specific Incidence Rates of Thyroid cancer, 2008

CyCR: 2008, Age Specific, Crude and WASR Incidence Rates for C73 Thyroid cancer		
	Male	Female
0-4		
5-9		
10-14		7.8
15-19	6.2	19.8
20-24		12.2
25-29	9.3	27.0
30-34		19.8
35-39	7.6	59.4
40-44	11.6	41.5
45-49	10.9	55.3
50-54	20.0	47.0
55-59	13.0	68.2
60-64	5.1	44.2
65-69	6.5	36.5
70-74	8.3	14.7
75-79	11.9	9.3
80-84		13.4
85+		17.0
Crude IR	6.4	29.7
WASR	5.3	24.6




Childhood Cancer

MECC Table 16. Female childhood cancers, 0-14 yrs, 2006-2008

Record status Confirmed
 Behaviour Malignant
 Population base Government controlled areas
 Sex Female


MECC ICD-10 categories	2006				2007				2008				Triennial Total
	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	
Lymphoid Leukaemia (C91)	3		1	4		1	1	2			1	1	7
Brain, & NS cancer (C70-C72)	1		1	2	1			1	1			1	4
Thyroid cancer (C73)			1	1			1	1			2	2	4
Other & Unspecified cancer (O&U)					1			1	1			1	2
Non-Hodgkin Lymphoma (C82-C85;C96)		1		1							1	1	2
Adrenal gland cancer (C74)	1			1	1			1					2
Myeloid Leukaemia (C92-C94)		1		1	1			1					2
Hodgkin disease (C81)			2	2									2
Trachea, Bronchus & Lung cancer (C33-C34)					1			1					1
Connective, Soft tissue cancer (C47;C49)									1			1	1
Bone cancer (C40-C41)			1	1									1
Colon cancer (C18)							1	1					1
Total	5	2	6	13	5	1	3	9	3		4	7	29



MECC Table 17. Male childhood cancers, 0-14 yrs, 2006-2008

Record status Confirmed
 Behaviour Malignant
 Population base Government controlled areas
 Sex Male

MECC ICD-10 categories	2006				2007				2008				Triennial Total
	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	
Lymphoid Leukaemia (C91)		1		1	2	1	1	4	1	2	1	4	9
Hodgkin disease (C81)			2	2			1	1		1	2	3	6
Non-Hodgkin Lymphoma (C82-C85;C96)		1		1		1	2	3					4
Brain, & NS cancer (C70-C72)	1		1	2		1		1			1	1	4
Bone cancer (C40-C41)	1			1			2	2		1		1	4
Other & Unspecified cancer (O&U)					1	1	1	3					3
Myeloid Leukaemia (C92-C94)		1	1	2	1			1					3
Kidney cancer (C64)	1			1	1			1					2
Connective, Soft tissue cancer (C47;C49)						1		1					1
Thyroid cancer (C73)			1	1									1
Nasopharynx cancer (C11)									1			1	1
Leukaemia unspec. (C95)		1		1									1
Total	3	4	5	12	5	5	7	17	2	4	4	10	39



h) Notifiability of cancer in the country

One of the aims of the National Cancer Strategy is the introduction of legislation on Notifiability of Cancer. A draft law enabling the Health Monitoring Unit to collect health data including confidential cancer data has been submitted to the Cyprus Legal Service for review.

Although the draft law is a general instrument for collection of health data, it will allow the government to issue regulations on specific health information topics, including cancer. Such regulations will specify the details of data items to be collected. The draft was prepared taking into account the recommendations of MECC Standard Operating Procedures. Comments by stakeholders were received and they were taken into account. We hope the draft will soon be going to Parliament.

i) Linking up with death certificates

The quality of **death certification** and codification has improved since 2004. Coding is done by Health Monitoring Unit, on multiple and underlying causes of death. Manual and automated coding is done using the MMDS (SUPERMICAR, MICAR and ACME/TRANSAX) software. About 90% of deaths are coded automatically. The rest need to be coded manually by application of the ICD-10 rules for mortality. ICD-10 updates are applied for the corresponding year according to the latest version of ACME. Querying of death certificates is done on a regular basis by telephone and/or fax. The coverage of deaths in Cypriot residents, including those dying abroad, has improved significantly in recent years.

It is now **possible to link** the Death Registry to the Cancer Registry by using the patients' national ID number. In a small proportion of deaths this is not possible because of the absence of a national ID in the death register or the cancer register or because of errors in recording the ID. The great majority of cases can, however, be linked. In 2011 we continued the linkage procedure introduced in 2009. This allows the uploading of a significant number of Death Certificate Notified (DCN) cancers. In Cyprus there are more than 1000 annual deaths with cancer recorded as the underlying cause of death. Some more certificates have cancer mentioned in the multiple causes. All such death certificates are imported into CanReg4 as pending cases of cancer. They go through the usual checks for duplicates and they are either confirmed as new cases or deleted. Before deletion, any updates on followup dates or other data items are done in CanReg4. A substantial number of these cases remain as Death Certificate Only (DCO) cases because of difficulties with follow-back procedures. At present, the percentage of DCO cases for the period 2006-2008 is around 10%.

This linkage has **improved the completeness** of cancer registration in Cyprus. However, the percentage of DCO cases is still relatively high. It has also made it possible to improve the completeness and accuracy of follow-up data. We hope that this will soon enable the calculation of cancer survival. Some active follow-up may need to be done for previous years but this is time and resource consuming. **Follow-back** of the DCO cases is not easy. It requires a lot of active casefinding activity. It often needs contacting general practitioners and private physicians. We have estimated that about 50% of these cases are certified by non hospital doctors. Record keeping in doctors' offices is not always complete. The registrars have difficulty in getting the cooperation of private physicians. Existing staff cannot cover all of this new workload.

j) Local activities

Cancer cluster investigations were conducted following claims by local communities. Some statistical clusters, for specific types of cancer, were identified, but they involved small numbers of cases. They could not lead to concrete conclusions. We also identified a smaller number of possibly meaningful clusters, but no meaningful clusters have been identified. As a result of this activity, the problem of numerous community cancer concerns, that had been raised by local authorities or members of

parliament, during the past ten years, appears to be coming to a conclusion. The relevant reports were prepared by the Cancer Registry and sent to community leaders, members of parliament and other stakeholders. The recent improvements in the quality and completeness of cancer registration were well documented and publicized. This seems to have made it possible to provide adequate reassurance to people.

The **Registry Data is requested** and broadly used by many professionals for presentations, reporting and use in scientific work. There is a growing volume for such requests and on many occasions they are heard or appear in the media.

A proposal for a project by **TEPAK University** to create the first mortality and cancer map of Cyprus is awaiting approval for funding. There is no feed-back yet.

The Cyprus **Institute of Neurology and Genetics** has shown interest in cooperating with the Cyprus Cancer Registry in order to write a Report on Descriptive Cancer Epidemiology in Cyprus. A number of meetings have taken place where options for making progress on this proposal were discussed.

The Cyprus Cancer Registry has been invited by the newly appointed **National Cancer Committee** to discuss ways of cooperation for further strengthening the position of cancer registration in Cyprus. Problematic areas and possibilities for improvement have been discussed. A report on the current status of the registry has been requested by the NCC. This is under preparation.

Clinical coding in public hospitals has made significant progress in 2010. The number of coders and their training and experience have improved. However it is not yet possible to cover all cases. Clinical coding is under the direction of the Health Monitoring Unit. Some degree of priority is given to coding oncology cases. The gradual increase in coverage and quality of codification of diagnoses and medical procedures is expected to improve the possibility of exporting electronic files from the public hospitals to the cancer registry.

Current casefinding procedures regarding the **collection of microscopy reports** have improved from purely manual procedures to a mixture of manual and electronic means. At least one pathology laboratory has cooperated in providing histology reports and listings in electronic format instead of paper reports. The selection of histology reports with reportable cancers is now done by the cancer registrars instead of the histology clerks. This has improved the completeness of casefinding. The previous methodology resulted in missing a number of reportable cases of cancer.

In 2010 the **speed of data entry** has improved significantly. The most significant factor in speeding up data entry has been the hard, voluntary work of the registry staff. It has also been improved as a result of importing a large volume of demographic and some tumour data in electronic form. Improvements in the organization of the work of casefinding and abstraction have also helped speed up data entry. Electronic lists of cases have been used instead of paper based lists.

It is noteworthy that this increased speed in data entry has been achieved, in parallel with the recent **increase in workload**. More work is needed due to the new **treatment and follow-up data** items and the increased annual **Number of new cases** of cancer.

Data for 2008 were completed at the time of writing this report, that is in the middle of September 2012. We hope that we shall finish data entry for 2009 in the summer of 2013.

k) Problems

Medical Records in some institutions remain incomplete and some are difficult to locate. However the implementation of an Integrated Government Hospitals Health Information System is making progress. This is expected to facilitate the abstracting of cases from state hospitals.

Although linkage with the Causes of Death Register and the Civil Death Register has been achieved, the problem of previous incomplete registration and low quality certification remains a major problem.

There is a need to review the staffing **needs** of the Cancer Registry.

Doctors' cooperation needs to be further strengthened in order to provide more accurate information on cancer cases. Without legislation to make cancer a notifiable disease the problem will persist.

Treatment data for 2007 is difficult to complete because almost all of the casefinding and abstracting procedures were completed without recording treatment data. Importing such data from BOCOC has not realized yet, because of difficulties in exporting files from the center's database. Some of these data may be possible to import electronically or gradually recorded manually while abstracting and resolving new cases in the years ahead.

Cancer is **not yet a notifiable disease** but appropriate legislation is in the process of being introduced.

APPENDIX I. CyCR Cancer Registration Form

ΑΡΧΕΙΟ ΚΑΡΚΙΝΟΥ ΚΥΠΡΟΥ - ΜΟΝΑΔΑ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΥΓΕΙΑΣ ΕΝΤΥΠΟ ΚΑΤΑΓΡΑΦΗΣ ΔΕΔΟΜΕΝΩΝ - Εμπιστευτικό Έγγραφο του Υπουργείου Υγείας

PATIENT					
NATIONAL ID:	BOCOC:			Regi No:	
<input type="text"/>	<input type="text"/>			<input type="text"/>	
FIRST NAME	SURNAME	FATHER	Sex:		
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Birth Date:	Ethnicity:	1 Greek	5 Latin	1 Male	
<input type="text"/>	<input type="text"/>	2 Turk	7 Other (Non-EU)	2 Female	
		3 Maronite	8 European Union	3 Herma.	
		4 Armenian	9 Unknown	9 Unknown	
District of Birth:	BirthP:	BirthP Town:			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
ADDRESS AND SOCIOECONOMIC					
STREET No TEXT		POST C	Residential status:		
<input type="text"/>		<input type="text"/>	<input type="text"/>		
DISTR-TOWN-QUARTER		1 Cyprus			
<input type="text"/>		2 CY - Turkish control			
		3 British Bases			
		4 Other EU countries			
		8 Other non-EU			
		9 Unknown			
Resi District:	Resi:	Resi Town:			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
Strt:	Strt Town:	Strt Odos:			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
Smoking history:	Marital status:	TELEPHONES			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
0 Never smoked, 1 Current smoker	1 Single, nev. mar. 2 Married 3 Separated				
2 Former smoker 9 Unknown sm. hist.	4 Divorced 5 Widowed 9 Unknown				
Occupation Category:	Occu:	Occupation:			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
TUMOR					
DATE ADMISSION:			MPTot:	MPSeq:	
<input type="text"/>			<input type="text"/>	<input type="text"/>	
Incidence date	AGE	SeqNo:	PRIMARY SITE TEXT	Behavior:	
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	
Topography:				Icd10:	2 In situ
<input type="text"/>	<input type="text"/>			<input type="text"/>	3 Malignant
MORPHOLOGY TEXT	ICD03	Basis of Diagnosis			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
Histology code	0 Death certificate only				
<input type="text"/>	1 Clinical only				
	2 Clin.Invest. (incl. X-ray, US etc.)				
	3 Exploratory surgery/autopsy				
	4 Specific biochem and/or immun. test				
	5 Cytology or hematology				
	6 Histology of metastases				
	7 Histology of primary				
	8 Autopsy with conc. or prev. histology				
	9 Unknown				
SEER SUMMARY STAGE TEXT	ICCC:				
<input type="text"/>	<input type="text"/>				
Laterality:	SEER Summary Stage:	Grade / Diff:			
<input type="text"/>	<input type="text"/>	<input type="text"/>			
0 Not a paired site	0 In situ	1 Stage I; well differentiated			
1 Right	1 Localized (Stage I for lymphomas)	2 Stage II; moderately differentiated			
2 Left	2 Regional by Direct Extension	3 Stage III; poorly differentiated			
3 Unilateral NOS	3 Regional by Lymph Nodes	4 Stage IV; undifferentiated, anaplastic			
4 Bilateral	4 Regional by both DE and LNs	5 T-cell; T-precursor			
9 Unknown / midline	5 Regional NOS (Stage II for lymphomas)	6 B-cell; Pre-B; B-precursor			
	7 Distant (Stage III or IV for lymphomas)	7 Null cell; Non T-non B			
	9 Unknown, undetermined	8 NK cell			
		9 Unknown/not stated/non applicable			

SOURCES

BOCOC: Regi No:

NOTIFIER-CERTIFIER

Notified by PatNo 1:

Contact Phys: PatNo 4:

Hospital-Clinic PatNo 3:

HISTOPATH1 HISTOPATH1 HISTOPATH1

Histologist 1: Histologist 2: Histologist 3:

Place of Diagnosis PatNo 1:

Hospital From: PatNo 2:

Hospital To PatNo 3:

FOLLOWUP

Vital status: 0 Alive
 1 Dead

DateLC:

UCOD: 0 Still alive
 1 Died of cancer
 2 Died of non-cancer
 9 Died of unknown cause

TREATMENT

0 Treatment NOT GIVEN
 1 Treatment GIVEN
 7 Patient REFUSED
 8 RECOMMENDED, Unknown if Received
 9 UNKNOWN

Date First Cancer Treatment

Cancer Surgery given? Date of Cancer Surgery

Radiotherapy given? Date of Radiotherapy

Chemotherapy given? Date of Chemotherapy

Hormone therapy given? Date of Hormone therapy

Immunotherapy given? Date of Immunotherapy

Other treatment given? Date of Other treatment

Notes:

2 / 2 Printed: 25/06/2010

APPENDIX II. CanReg4 Frequencies 1998-2012

Frequencies by Year

CanReg4

19/09/2012

25717

Number of cases by year by Record status / Sex

	Pending			Total
	Unknown	Male	Female	
1998	0	0	0	0
1999	0	0	0	0
2000	0	0	0	0
2001	0	0	0	0
2002	0	0	0	0
2003	0	0	0	0
2004	0	0	0	0
2005	0	0	0	0
2006	0	0	0	0
2007	0	0	2	2
2008	0	7	6	13
2009	22	1139	1030	2191
2010	0	870	949	1819
2011	0	934	983	1917
2012	0	204	233	437
-----	22	3154	3203	6379
	Confirmed			Total
	Unknown	Male	Female	
1998	0	807	860	1667
1999	0	821	843	1664
2000	0	938	851	1789
2001	0	993	961	1954
2002	0	1087	1020	2107
2003	0	1130	1099	2229
2004	0	1296	1165	2461
2005	0	1321	1224	2545
2006	2	1394	1250	2646
2007	0	1478	1469	2947
2008	0	1561	1492	3053
2009	0	75	126	201
2010	0	62	154	216
2011	0	80	157	237
2012	0	0	1	1
-----	2	13043	12672	25717

Number of cases by year by Basis of Diagnosis

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Death Certif: 0:	61	46	51	146	167	153	241	256	244	292	277	0	0	0	0	: 1934
2: Clinical Only: 1:	9	5	6	6	14	8	10	8	3	2	2	0	0	0	0	: 73
3: Clinical Inves: 2:	24	36	35	29	51	25	23	23	29	27	22	0	0	0	0	: 324
4: Surgery/Autp: 3:	9	6	6	0	1	0	0	0	2	0	1	0	0	0	0	: 25
5: Bioc/ImmTest: 4:	4	2	6	0	1	0	0	0	0	0	0	0	0	0	0	: 13
6: Cytol/Hemat: 5:	96	94	92	164	153	161	165	89	114	100	77	1	0	0	0	: 1306
7: Histol-Meta: 6:	18	25	62	68	84	85	86	101	85	115	90	1	1	3	0	: 824
8: Histol-Prim: 7:	1420	1444	1517	1529	1613	1775	1923	2053	2148	2402	2578	199	215	234	1	: 21051
9: Autop+Histol: 8:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
10: Unknown: 9:	26	6	14	12	23	22	13	15	21	9	5	0	0	0	0	: 166
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
-----																: 25717

Number of cases by year by Residential Status

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: CY GC: 1:	1651	1653	1784	1947	2104	2226	2448	2497	2496	2811	2907	195	209	237	1	: 25166
2: Occup: 2:	2	5	5	5	1	2	3	33	85	87	108	5	7	0	0	: 348
3: Brit B: 3:	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	: 4
4: EU: 4:	0	0	0	0	1	0	0	2	15	22	5	0	0	0	0	: 45
5: Other: 8:	0	0	0	0	0	0	7	12	19	6	5	0	0	0	0	: 49
6: Unkn: 9:	14	5	0	2	1	0	3	0	31	21	27	1	0	0	0	: 105
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
-----																: 25717

Number of cases by year by Ethnicity

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Greek: 1:	1552	1550	1657	1806	1918	2040	2220	2214	2179	2456	2532	184	195	214	1	: 22718
2: Turkish: 2:	7	5	4	3	3	0	1	28	82	80	104	5	4	0	0	: 326
3: Maronite: 3:	0	4	2	1	2	2	4	5	1	7	0	0	0	0	0	: 28
4: Armenian: 4:	11	10	8	7	15	16	10	9	6	12	10	0	0	0	0	: 114
5: Latin: 5:	0	2	0	0	0	0	0	1	0	2	0	0	0	0	0	: 5
6: Other: 6:	29	28	31	50	62	50	68	84	27	7	1	0	0	0	0	: 437
7: Non-EU: 7:	57	52	62	62	68	85	102	116	62	77	61	6	7	4	0	: 821
8: EU: 8:	10	13	21	14	25	32	38	79	217	261	254	3	6	9	0	: 982
9: Unknown: 9:	1	0	4	11	14	4	18	9	72	45	91	3	4	10	0	: 286
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

25717

Number of cases by year by Sex

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Male: 1:	807	821	938	993	1087	1130	1296	1321	1394	1478	1561	75	62	80	0	: 13043
2: Female: 2:	860	843	851	961	1020	1099	1165	1224	1250	1469	1492	126	154	157	1	: 12672
3: Herma: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
4: Unknow: 9:	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	: 2
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

25717

Number of cases by year by Summary Stage

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: In situ: 0:	68	46	29	40	60	70	75	83	75	119	93	0	0	0	0	: 758
2: Local (I): 1:	905	773	856	801	853	897	1033	954	961	1000	963	125	133	148	1	: 10403
3: Reg DE: 2:	83	192	174	183	169	192	189	204	227	236	277	17	19	15	0	: 2177
4: Reg LN: 3:	174	164	122	146	130	143	134	144	148	188	205	21	21	23	0	: 1763
5: Reg Both: 4:	43	83	116	110	97	94	110	124	184	166	137	16	10	14	0	: 1304
6: Reg NOS (II): 5:	1	15	15	28	11	35	25	11	17	24	42	0	0	0	0	: 224
7: Dist (III/IV): 7:	283	245	274	293	346	364	400	412	417	519	563	8	2	6	0	: 4132
8: Unkn: 9:	110	146	203	353	441	434	495	613	617	695	773	14	31	31	0	: 4956
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

25717

Number of cases by year by Grade/Differentiation

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: I; Well Di: 1:	587	514	319	253	248	234	296	264	296	286	303	45	61	34	0	: 3740
2: II; Mod Dif: 2:	366	441	558	569	586	655	720	704	690	799	752	8	12	9	0	: 6869
3: III; Poor Di: 3:	378	320	348	302	303	315	280	450	523	620	760	0	0	5	0	: 4604
4: IV; Undif/A: 4:	5	9	15	18	9	12	14	7	22	17	16	2	0	0	0	: 146
5: T-cell: 5:	5	3	3	1	4	16	15	5	5	9	8	0	0	0	0	: 74
6: B-cell: 6:	83	93	78	69	97	103	120	129	123	104	125	1	0	1	0	: 1126
7: Null: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
8: NK: 8:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
9: Unkn: 9:	243	284	468	742	860	894	1016	986	987	1112	1088	145	143	188	1	: 9157
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

25717

Number of cases by year by Laterality

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not pair: 0:	1103	1093	1202	1260	1390	1443	1659	1719	1787	1970	2038	168	191	203	1	: 17227
2: Right: 1:	182	213	221	274	334	334	348	361	343	385	421	17	10	17	0	: 3460
3: Left: 2:	216	212	245	284	269	324	307	297	329	363	391	11	13	13	0	: 3274
4: Unilatera: 3:	0	0	0	3	0	0	2	1	0	0	3	0	1	1	0	: 11
5: Bilatera: 4:	7	10	5	15	21	19	21	21	15	20	23	0	0	0	0	: 177
6: NoInfo/M: 9:	159	136	116	118	93	109	124	146	172	209	177	5	1	3	0	: 1568
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

25717

Number of cases by year by ICD-10 group

Male

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
Lip	0	3	4	2	2	1	7	3	6	9	6	0	0	0	0	43: C00
Tongue	3	0	5	6	6	6	6	8	3	2	8	0	0	0	0	53: C01-C02
Mouth	4	4	3	3	2	4	5	3	4	9	6	0	0	0	0	47: C03-C06
Salivary glands	2	1	2	3	2	2	0	5	5	3	4	0	0	0	0	29: C07-C08
Tonsil	1	0	2	0	1	1	0	0	2	2	2	0	0	0	0	11: C09
Other Oropharynx	0	0	1	1	5	1	0	1	1	0	2	0	0	0	0	12: C10
Nasopharynx	1	3	1	2	3	4	3	1	1	2	7	0	0	0	0	28: C11
Hypopharynx	1	0	0	1	0	2	0	0	0	1	0	0	0	0	0	5: C12-C13
Pharynx unspec.	0	2	0	0	1	1	0	1	0	0	0	0	0	0	0	5: C14
Oesophagus	4	7	5	5	6	4	2	7	12	10	5	0	0	0	0	67: C15
Stomach	27	28	32	35	46	36	39	37	49	51	54	0	0	0	0	434: C16
Small intestine	2	3	4	3	5	0	1	2	2	2	2	0	0	0	0	26: C17
Colon	62	68	64	74	74	80	112	109	112	134	123	0	0	0	0	1012: C18
Rectum	28	32	41	30	41	42	42	41	58	53	62	0	0	0	0	470: C19-C20
Anus	1	2	0	2	1	0	3	0	1	4	2	0	0	0	0	16: C21
Liver	13	16	18	11	22	21	19	25	26	35	23	0	0	0	0	229: C22
Gallbladder etc.	9	12	5	12	8	9	13	9	11	13	8	0	0	0	0	109: C23-C24
Pancreas	19	16	20	21	23	26	26	29	22	36	31	0	0	0	0	269: C25
Nose, sinuses etc.	3	3	0	0	0	0	1	1	2	2	1	0	0	0	0	13: C30-C31
Larynx	19	12	10	17	14	10	18	21	19	24	35	0	0	0	0	199: C32
Trachea, Bronchus, Lung	90	107	118	144	139	137	147	151	146	173	198	0	0	0	0	1550: C33-C34
Other Thoracic organs	1	2	0	4	2	9	0	3	3	5	4	0	0	0	0	33: C37-C38
Bone	10	3	3	9	4	8	7	1	6	5	4	0	0	0	0	60: C40-C41
Melanoma of Skin	9	11	12	12	17	13	14	17	16	30	33	0	0	0	0	184: C43
Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C44
Mesothelioma	2	1	3	4	1	6	5	3	11	7	9	0	0	0	0	52: C45
Kaposi sarcoma	2	3	4	0	2	0	3	3	2	1	4	0	0	0	0	24: C46
Connective, Soft tissue	10	7	2	12	7	11	10	12	12	19	15	0	0	0	0	117: C47;C49
Breast	2	7	3	0	3	3	6	4	8	5	7	0	0	0	0	48: C50
Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C51
Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C52
Cervix Uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C53
Corpus Uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C54
Uterus unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C56
Other Female Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C58
Penis	5	3	3	4	2	3	7	6	6	6	11	0	0	0	0	56: C60
Prostate	166	161	257	247	259	260	359	358	353	363	392	0	0	0	0	3175: C61
Testis	11	16	16	17	15	26	30	24	23	24	26	31	24	32	0	315: C62
Other male genital	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	3: C63
Kidney	22	15	23	27	29	24	29	24	27	18	29	1	0	0	0	268: C64
Renal Pelvis	2	1	1	0	2	3	1	4	2	1	0	0	0	0	0	17: C65
Ureter	1	0	0	0	0	3	1	2	3	2	0	0	0	0	0	12: C66
Bladder	70	88	108	85	82	104	89	112	123	121	131	0	0	0	0	1113: C67
Other Urinary organs	2	1	0	4	1	3	1	0	2	2	1	0	0	0	0	17: C68
Eye	1	0	3	2	0	1	3	1	2	1	0	0	0	0	0	14: C69
Brain, Nervous system	24	17	24	16	20	20	27	16	32	28	25	0	0	0	0	249: C70-C72
Thyroid	12	7	10	15	13	17	19	16	19	21	25	42	38	47	0	301: C73
Adrenal gland	2	0	3	0	2	0	1	1	0	1	3	0	0	0	0	13: C74
Other Endocrine	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1: C75
Hodgkin disease	8	8	9	14	11	14	8	21	18	12	15	0	0	0	0	138: C81
Non-Hodgkin lymphoma C85;C96	45	46	41	28	44	59	65	60	58	47	58	1	0	1	0	553: C82-
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1: C88
Multiple Myeloma	15	14	6	4	15	18	23	20	21	23	17	0	0	0	0	176: C90
Lymphoid Leukaemia	22	24	18	20	27	21	26	29	24	28	26	0	0	0	0	265: C91
Myeloid Leukaemia	10	21	12	11	13	8	19	13	20	24	27	0	0	0	0	178: C92-C94
Leukaemia unspec.	1	2	4	9	7	5	11	19	9	5	13	0	0	0	0	85: C95
Other & unspecified	28	26	30	61	84	80	58	60	64	58	53	0	0	0	0	602: Other
All sites Total	772	804	930	978	1064	1106	1266	1284	1346	1423	1507	75	62	80	0	12697
All sites but C44	772	804	930	978	1064	1106	1266	1284	1346	1423	1507	75	62	80	0	12697
Non-Malignant	35	17	8	15	23	24	30	37	48	55	53	0	0	0	0	345

Female

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
Lip	0	0	1	1	1	2	1	2	1	0	1	0	0	0	0	10: C00
Tongue	3	4	2	2	6	3	1	4	3	3	3	0	0	0	0	34: C01-C02
Mouth	2	3	1	1	2	2	3	1	1	4	4	0	0	0	0	24: C03-C06
Salivary glands	4	4	0	3	0	2	0	3	1	4	4	0	0	0	0	25: C07-C08
Tonsil	0	0	0	1	0	0	0	1	0	1	1	0	0	0	0	4: C09
Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C10
Nasopharynx	1	2	1	2	1	1	0	1	0	1	2	0	0	0	0	12: C11
Hypopharynx	0	0	0	2	0	1	1	0	0	1	0	0	0	0	0	5: C12-C13
Pharynx unspec.	0	2	1	0	0	1	0	0	0	0	0	0	0	0	0	4: C14
Oesophagus	3	0	3	1	1	4	0	1	3	4	5	0	0	0	0	25: C15
Stomach	27	22	23	25	22	15	23	18	25	28	42	0	0	0	0	270: C16
Small intestine	0	2	0	0	1	0	2	1	1	2	3	0	0	0	0	12: C17
Colon	59	62	72	62	71	67	97	89	99	139	95	0	0	0	0	912: C18
Rectum	19	24	35	29	23	25	26	42	41	40	39	0	0	0	0	343: C19-C20
Anus	1	2	0	1	1	1	1	3	4	5	4	0	0	0	0	23: C21
Liver	5	6	7	4	13	8	7	11	13	16	11	0	0	0	0	101: C22
Gallbladder etc.	13	16	11	16	13	7	11	15	11	11	13	0	0	0	0	137: C23-C24
Pancreas	12	13	16	18	16	10	19	22	23	32	34	0	0	0	0	215: C25
Nose, sinuses etc.	0	0	0	4	2	0	0	0	1	3	0	0	0	0	0	10: C30-C31
Larynx	1	1	2	4	0	2	1	3	3	1	1	0	0	0	0	19: C32
Trachea, Bronchus, Lung	19	27	28	29	37	24	44	44	59	48	57	0	0	0	0	416: C33-C34
Other Thoracic organs	2	3	1	1	3	0	0	0	2	6	4	0	0	0	0	22: C37-C38
Bone	2	3	2	9	6	4	7	4	2	2	0	0	0	0	0	41: C40-C41
Melanoma of Skin	18	13	17	19	18	21	16	16	18	29	36	0	0	0	0	221: C43
Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C44
Mesothelioma	1	3	1	1	1	2	2	3	3	1	1	0	0	0	0	19: C45
Kaposi sarcoma	1	0	1	1	4	1	1	1	1	1	0	0	0	0	0	12: C46
Connective, Soft tissue	12	9	5	5	10	12	13	11	9	8	17	0	0	0	0	111: C47;C49
Breast	277	286	280	323	337	407	400	418	431	498	484	0	0	0	0	4141: C50
Vulva	12	5	4	6	10	8	9	8	6	8	9	0	0	0	0	85: C51
Vagina	0	2	2	1	2	0	0	1	2	1	0	0	0	0	0	11: C52
Cervix Uteri	27	26	15	17	19	18	27	25	30	30	27	0	0	0	0	261: C53
Corpus Uteri	51	48	72	56	56	70	66	83	72	69	83	1	0	0	0	727: C54
Uterus unspec.	8	1	3	5	4	2	4	10	8	3	9	0	0	0	0	57: C55
Ovary	47	35	33	40	34	24	41	36	35	48	55	0	0	0	0	428: C56
Other Female Genital	0	0	0	0	1	1	0	1	2	3	4	0	0	0	0	12: C57
Placenta	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1: C58
Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C63
Kidney	8	16	13	11	18	18	10	11	14	11	19	0	0	0	0	149: C64
Renal Pelvis	1	0	0	0	0	1	0	1	0	1	2	0	0	0	0	6: C65
Ureter	0	0	0	2	0	1	0	0	0	0	1	0	0	0	0	4: C66
Bladder	16	18	13	16	21	15	27	23	15	23	30	0	0	0	0	217: C67
Other Urinary organs	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	3: C68
Eye	3	0	2	0	1	1	1	4	2	1	2	0	0	0	0	17: C69
Brain, Nervous system	17	16	20	22	16	19	17	14	23	30	28	0	0	0	0	222: C70-C72
Thyroid	44	34	34	44	39	55	50	54	69	83	122	125	154	157	1	1065: C73
Adrenal gland	0	0	2	1	0	2	0	3	3	2	0	0	0	0	0	13: C74
Other Endocrine	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	3: C75
Hodgkin disease	10	12	11	17	12	16	15	12	14	9	14	0	0	0	0	142: C81
Non-Hodgkin lymphoma	33	36	29	24	37	37	43	45	49	48	55	0	0	0	0	436: C82-
C85;C96																
Immunoproliferative dis.	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1: C88
Multiple Myeloma	7	8	5	10	13	18	21	17	11	27	27	0	0	0	0	164: C90
Lymphoid Leukaemia	17	14	10	16	11	17	23	26	20	13	13	0	0	0	0	180: C91
Myeloid Leukaemia	10	11	11	10	9	12	14	11	15	9	12	0	0	0	0	124: C92-C94
Leukaemia unspec.	3	3	2	6	10	8	9	11	7	11	6	0	0	0	0	76: C95
Other & unspecified	31	19	37	59	75	73	57	55	48	60	52	0	0	0	0	566: Other
All sites Total	827	813	829	928	977	1039	1111	1166	1200	1379	1431	126	154	157	1	12138
All sites but C44	827	813	829	928	977	1039	1111	1166	1200	1379	1431	126	154	157	1	12138
Non-Malignant	33	30	22	33	43	60	54	58	50	90	61	0	0	0	0	534

Number of cases by year by Cause of death

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Still : 0:	866	841	834	926	956	1122	1301	1428	1564	1765	2000	196	214	236	1	: 14250
2: Cancer: 1:	417	541	627	742	804	792	885	864	898	1069	906	4	1	0	0	: 8550
3: Non Ca: 2:	112	149	214	209	225	139	147	102	127	34	89	1	0	0	0	: 1548
4: Unkn: 9:	255	127	107	70	109	166	119	138	46	78	57	0	1	1	0	: 1274
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	17	6	7	7	13	10	9	13	11	1	1	0	0	0	0	: 95

	25717															

Number of cases by year by Vital Status

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Alive: 0:	866	841	834	926	956	1122	1301	1428	1564	1764	1998	194	214	236	1	: 14245
2: Dead: 1:	801	823	955	1028	1151	1107	1160	1117	1082	1183	1055	7	2	1	0	: 11472
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

	25717															

Number of cases by year by Month of incidence

	unk	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	TOT
1998	4	130	144	144	138	143	170	155	113	127	126	121	152	1667
1999	0	107	123	149	139	138	154	163	116	117	132	174	152	1664
2000	2	133	155	146	141	161	156	156	130	153	158	174	124	1789
2001	1	150	141	186	135	179	179	186	144	155	195	179	124	1954
2002	2	139	179	189	193	179	178	217	138	169	177	187	160	2107
2003	2	159	167	171	173	212	178	201	145	210	228	202	181	2229
2004	2	181	193	238	201	211	249	219	163	204	195	229	176	2461
2005	1	210	188	220	197	182	289	231	178	211	215	221	202	2545
2006	1	220	216	238	167	243	260	216	199	219	240	220	207	2646
2007	1	229	224	304	222	288	249	246	175	249	272	274	214	2947
2008	3	270	247	249	266	312	272	277	202	257	253	249	196	3053
2009	2	12	12	21	12	17	12	13	19	21	21	24	15	201
2010	0	12	23	21	21	25	16	8	12	18	24	14	22	216
2011	0	15	21	22	19	20	25	19	14	22	15	25	20	237
2012	0	0	0	1	0	0	0	0	0	0	0	0	0	1

	21	1967	2034	2298	2024	2310	2387	2307	1748	2132	2251	2293	1945	25717

Number of cases by year by Cancer Therapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	0	4	77	2	0	0	: 83
2: Given: 1:	0	0	0	0	0	0	0	0	2	8	898	2242	198	215	236	1 : 3800
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	: 5
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	1667	1664	1789	1954	2107	2229	2461	2543	2637	1	0	0	0	0	0	: 19052
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	1	317	723	1	1	1	: 1044
Errors:	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	: 6
Missing:	0	0	0	0	0	0	0	0	0	1727	0	0	0	0	0	: 1727

	25717															

Number of cases by year by Cancer Surgery

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	0	2	26	0	0	0	: 28
2: Given: 1:	0	0	0	0	0	0	1	0	2	7	81	1655	197	215	235	1 : 2394
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	0	3	0	0	1	: 4
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	: 2
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1667	1664	1789	1954	2107	2228	2461	2543	2639	2864	1367	4	1	1	0	: 23289

	25717															

Number of cases by year by Radiotherapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	1	0	0	0	0	0	0	1	544	573	646	11	0	0	0	: 1776
2: Given: 1:	4	2	2	0	2	3	8	21	778	831	777	87	135	152	1	: 2803
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1662	1662	1787	1954	2105	2226	2453	2523	1324	1543	1628	103	81	85	0	: 21136

																25717

Number of cases by year by Chemotherapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	1	3	198	0	0	0	0	: 202
2: Given: 1:	0	0	0	0	0	0	0	0	3	45	984	25	12	16	0	: 1085
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	: 5
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1667	1664	1789	1954	2107	2229	2461	2545	2642	2899	1866	176	204	221	1	: 24425

																25717

Number of cases by year by Hormone therapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	3	183	0	0	0	0	: 186
2: Given: 1:	0	0	0	0	0	0	0	0	0	18	994	131	159	166	1	: 1469
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1667	1664	1789	1954	2107	2229	2461	2545	2646	2926	1875	70	57	71	0	: 24061

																25717

Number of cases by year by Immunotherapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	: 1
2: Given: 1:	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	: 5
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1667	1664	1789	1954	2107	2229	2461	2545	2646	2947	3047	201	216	237	1	: 25711

																25717

Number of cases by year by Other therapy

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
2: Given: 1:	0	0	0	0	0	0	0	0	0	0	8	1	0	0	0	: 9
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
4: Recomm: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: CHECK !!!: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
6: N/A: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
7: Unknown: 9:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1667	1664	1789	1954	2107	2229	2461	2545	2646	2947	3045	200	216	237	1	: 25708

																25717

Number of cases by year by Topography

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
1: LIP: 0:	0	3	5	3	3	3	9	5	7	9	7	0	0	0	0	54
2: TONGUE - BA: 1:	2	0	1	4	8	4	0	5	2	1	2	0	0	0	0	29
3: TONGUE - OT: 2:	4	4	7	4	6	7	8	7	5	4	10	0	0	0	0	66
4: GUM: 3:	1	0	0	0	0	0	2	1	1	0	1	0	0	0	0	6
5: MOUTH - FLO: 4:	0	0	1	2	1	0	0	1	1	2	1	0	0	0	0	9
6: MOUTH - PAL: 5:	3	3	2	1	1	1	2	0	2	4	2	0	0	0	0	21
7: MOUTH - OTH: 6:	2	4	1	1	2	5	5	2	2	8	6	0	0	0	0	38
8: MOUTH - PAR: 7:	4	2	3	5	1	5	0	4	5	6	6	0	0	0	0	41
9: MOUTH - GLA: 8:	2	4	2	1	1	0	1	5	1	2	2	0	0	0	0	21
10: TONSILS: 9:	2	0	2	2	5	1	1	4	3	4	4	0	0	0	0	28
11: OROPHARYNX: 10:	0	0	1	1	5	2	0	1	1	0	2	0	0	0	0	13
12: NASOPHARYNX: 11:	2	5	2	4	5	7	3	3	1	4	11	0	0	0	0	47
13: PYRIFORM SI: 12:	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	2
14: HYPOPHARYNX: 13:	1	0	0	1	0	3	1	0	0	2	0	0	0	0	0	8
15: OTHER PHARY: 14:	0	4	1	0	2	2	0	1	0	0	0	0	0	0	0	10
16: ESOPHAGUS: 15:	7	8	8	6	7	8	2	8	15	14	10	0	0	0	0	93
17: STOMACH: 16:	61	56	62	63	75	59	71	61	84	82	101	0	0	0	0	775
18: SMALL INTES: 17:	3	5	4	3	6	2	4	3	4	6	6	0	0	0	0	46
19: COLON: 18:	124	130	137	138	146	148	214	201	214	276	219	0	0	0	0	1947
20: RECTOSIGMOI: 19:	7	9	16	16	11	24	23	23	32	24	28	0	0	0	0	213
21: RECTUM: 20:	40	49	60	43	53	44	46	61	68	69	74	0	0	0	0	607
22: ANUS, ANAL : 21:	2	5	0	3	2	1	4	3	6	9	6	0	0	0	0	41
23: LIVER: 22:	20	22	26	16	35	29	26	35	40	51	33	0	0	0	0	333
24: GALL BLADDE: 23:	20	24	15	25	19	9	15	13	11	16	16	0	0	0	0	183
25: BILE TRACT: 24:	2	4	1	3	5	7	9	14	11	10	7	0	0	0	0	73
26: PANCREAS: 25:	31	29	36	39	39	36	45	51	45	68	66	0	0	0	0	485
27: GASTROINTES: 26:	1	3	2	5	10	4	3	9	7	1	9	0	0	0	0	54
28: EAR/NOSE: 30:	3	3	0	3	2	0	1	1	3	4	0	0	0	0	0	20
29: ACCESSORY S: 31:	0	1	0	1	0	0	0	1	1	1	1	0	0	0	0	5
30: LARYNX: 32:	20	16	14	22	16	13	21	27	23	26	37	0	0	0	0	235
31: TRACHEA: 33:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32: BRONCHUS, L: 34:	114	135	148	173	177	164	192	198	211	222	257	0	0	0	0	1991
33: THYMUS: 37:	0	0	1	2	3	4	0	0	1	5	4	0	0	0	0	20
34: HEART, PLEU: 38:	5	11	4	11	7	13	7	10	12	14	16	0	0	0	0	110
35: RESPIRATORY: 39:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36: BONES - LIM: 40:	7	4	2	8	5	4	6	2	4	5	3	0	0	0	0	50
37: BONES - OTH: 41:	4	2	3	9	5	8	8	6	2	2	2	0	0	0	0	51
38: BLOOD, SPLE: 42:	86	101	71	94	110	123	164	167	162	183	171	0	0	0	0	1432
39: SKIN: 44:	32	31	36	41	44	41	41	41	43	66	86	0	0	0	0	502
40: PERIPHERAL : 47:	2	1	0	0	1	1	1	0	0	0	0	0	0	0	0	6
41: PERITONEUM: 48:	5	5	3	0	2	4	3	3	4	3	9	0	0	0	0	41
42: SOFT TISSUE: 49:	20	10	7	12	13	19	18	21	21	26	27	0	0	0	0	194
43: BREAST: 50:	293	309	300	348	372	451	445	462	464	558	534	0	0	0	0	4536
44: VULVA: 51:	12	5	4	6	10	8	10	8	6	9	10	0	0	0	0	88
45: VAGINA: 52:	0	2	2	1	2	0	0	1	2	1	0	0	0	0	0	11
46: CERVIX UTER: 53:	33	34	18	21	27	28	28	33	37	39	33	0	0	0	0	331
47: CORPUS UTER: 54:	52	49	74	57	57	70	66	83	71	71	83	1	0	0	0	734
48: UTERUS, NOS: 55:	8	1	3	5	4	2	4	10	8	3	9	0	0	0	0	57
49: OVARY: 56:	47	35	33	40	34	24	41	35	37	48	55	0	0	0	0	429
50: FEMALE GEN.: 57:	1	0	0	0	1	1	0	1	2	3	4	0	0	0	0	13
51: PLACENTA: 58:	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
52: PENIS: 60:	5	3	3	4	2	3	7	6	7	7	12	0	0	0	0	59
53: PROSTATE: 61:	166	161	260	247	260	261	359	358	354	363	392	0	0	0	0	3181
54: TESTIS: 62:	12	16	16	17	19	28	32	24	25	25	27	31	24	33	0	329
55: MALE GEN.- : 63:	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	3
56: KIDNEY: 64:	32	33	37	38	47	42	39	35	41	29	50	1	0	0	0	424
57: RENAL PELVI: 65:	3	1	1	0	2	4	1	5	2	2	3	0	0	0	0	24
58: URETER: 66:	1	0	0	2	0	4	1	2	3	3	1	0	0	0	0	17
59: BLADDER: 67:	131	122	123	108	111	131	134	166	169	184	196	0	0	0	0	1575
60: URETHRA, OT: 68:	2	2	1	4	1	4	1	0	2	2	1	0	0	0	0	20
61: EYE: 69:	4	0	5	3	4	2	4	7	7	2	3	0	0	0	0	41
62: MENINGES: 70:	2	0	1	0	0	0	2	0	0	2	1	0	0	0	0	8
63: BRAIN: 71:	35	34	39	34	37	39	40	30	56	56	53	0	0	0	0	453
64: NERVOUS SYS: 72:	4	1	4	4	0	1	2	0	1	1	1	0	0	0	0	19
65: THYROID: 73:	56	41	44	59	52	73	69	70	88	105	148	167	192	204	1	1369
66: ADRENAL GLA: 74:	2	0	4	1	2	2	1	4	3	2	3	0	0	0	0	24
67: ENDOCRINE G: 75:	0	1	0	1	1	0	0	0	0	1	0	0	0	0	0	4
68: ILL-DEFINED: 76:	2	3	4	4	3	3	7	10	9	13	11	0	0	0	0	69
69: LYMPH NODES: 77:	70	69	66	68	78	95	112	105	104	84	106	1	0	0	0	958
70: UNKNOWN: 80:	55	48	63	114	148	148	100	91	93	105	75	0	0	0	0	1040
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

25717

APPENDIX III. Trends in WASR 1998-2008 (Revised Cy Populations 2011)

Graphs showing trends in World Age Standardised Incidence Rates for the most common cancers.

Figure 1. CyCR: Trends in WASR, All but C44




Figure 2. CyCR: Trends in WASR, C16 Stomach




Figure 3. CyCR: Trends in WASR, C18-20 Colorectal




Figure 4. CyCR: Trends in WASR, C33-C34 Tr., Br., Lung




Figure 5. CyCR: Trends in WASR, C50 Breast




Figure 6. CyCR: Trends in WASR, C53 Cervix uteri




Figure 7. CyCR: Trends in WASR, C54 Corpus Uteri




Figure 8. CyCR: Trends in WASR, C56 Ovary




Figure 9. CyCR: Trends in WASR, C61 Prostate




Figure 10. CyCR: Trends in WASR, C62 Testis




Figure 11. CyCR: Trends in WASR, C67 Bladder




Figure 12. CyCR: Trends in WASR, C70-C72 Brain & NS




Figure 13. CyCR: Trends in WASR, C73 Thyroid





Figure 14. CyCR: Trends in WASR, C81 Hodgkin disease




Figure 15. CyCR: Trends in WASR, C82-C85; C96 NHL




Figure 16. CyCR: Trends in WASR, C91 Lymphoid Leukemia




Figure 17. CyCR: Trends in WASR, C92-C94 Myeloid Leukemia





Figure 18. CyCR: Trends in WASR, O&U Other & Unspecified



APPENDIX IV. Childhood Cancer by ICC 2006-2008

CyCR: International Classification for Childhood Cancer 2006-2008

Incidence Tables

CanReg4 20/07/2012

Childhood_Rev_2006-2008_World

Date : 16/07/2012

Source : Revised Cyprus Populations 2011

Filter : Beha=3 and (Restat=1 or Restat=9)

Standard pop. : World

Ages	Male	Female	WSP
0	4670	4339	2400
1-4	17691	16621	9600
5-9	22747	21605	10000
10-14	27679	26269	9000
???			
	-----	-----	-----
Total:	72787	68834	31000

Incidence date range:

From 01/01/2006
 To 31/12/2008

From 01/01/2006
 To 31/12/2008

International Classification for Childhood Cancer

Male		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					
		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude	ASR
1	LEUKAEMIA, MYELOPRO/MYELODYS.DIS.	1	3	6	3	13	34%	100%	71.4	56.5	87.9	36.1	59.5	61.9
01a	Lymphoid leukaemia		3	4	2	9	24%	69%		56.5	58.6	24.1	41.2	43.4
01b	Acute myeloid leukaemia	1			1	2	5%	15%	71.4			12	9.2	9
01c	Chronic myeloproliferative			1		1	3%	8%			14.7		4.6	4.7
01d	Myelodysplas syn, myeloprolif.													
01e	Other/unspec leukaemia			1		1	3%	8%			14.7		4.6	4.7
2	LYMPHOMAS, RETICULOENDOTHELIAL			3	7	10	26%	100%			44	84.3	45.8	38.6
02a	Hodgkin lymphoma			1	5	6	16%	60%			14.7	60.2	27.5	22.2
02b	NHL (not Burkitt)			1	1	2	5%	20%			14.7	12	9.2	8.2
02c	Burkitt lymphoma			1		1	3%	10%			14.7		4.6	4.7
02d	Misc lymphoreticular													
02e	Unspecified lymphoma				1	1	3%	10%				12	4.6	3.5
3	CNS, INTRACRANIAL/SPINAL		1	1	1	3	8%	100%		18.8	14.7	12	13.7	14.1
03a	Ependymoma, choroid plexus													
03b	Astrocytoma													
03c	Intracranial/spinal embryonal				1	1	3%	33%				12	4.6	3.5
03d	Other glioma			1		1	3%	33%			14.7		4.6	4.7
03e	Oth.spec.intracranial/spinal													
03f	Unspec.intracranial/spinal		1			1	3%	33%		18.8			4.6	5.8
4	NEUROBLASTOMA, PER.NERV.CELL	1			1	2	5%	100%	71.4			12	9.2	9
04a	Neuro/ganglioneuroblastoma	1			1	2	5%	100%	71.4			12	9.2	9
04b	Other periph.nervous cell													
5	RETINOBLASTOMA							-						
6	RENAL TUMOUR		2			2	5%	100%		37.7			9.2	11.7
06a	Nephroblastoma, non-epithel.renal		2			2	5%	100%		37.7			9.2	11.7
06b	Renal carcinomas													
06c	Unspec.malig.renal													

7	HEPATIC TUMOUR					-								
07a	Hepatoblastoma													
07b	Hepatic carcinoma													
07c	Unspec.malig.hepatic													
8	MALIGNANT BONE TUMOUR		1	2	3	8%	100%	14.7	24.1	13.7	11.7			
08a	Osteosarcoma			1	1	3%	33%		12	4.6	3.5			
08b	Chondrosarcoma													
08c	Ewing, related bone sarcoma		1	1	2	5%	67%	14.7	12	9.2	8.2			
08d	Other spec. malig. bone													
08e	Unspec. malig. bone													
9	SOFT TISSUE, EXTRAOSS.SARCOMA		2	1	3	8%	100%	37.7	14.7	13.7	16.4			
09a	Rhabdomyosarcoma		2	1	3	8%	100%	37.7	14.7	13.7	16.4			
09b	Fibrosarc,periph.nerve sheath													
09c	Kaposi sarcoma													
09d	Oth.spec.soft tissue sarcoma													
09e	Unspec.soft tissue sarcoma													
10	GERM CELL,TROPHOBLAST,GONAD													
10a	Intracranial/spinal germ cell													
10b	Malig.extracran/gonad germ cell													
10c	Malignant gonadal germ cell													
10d	Gonadal carcinomas													
10e	Other malignant gonadal													
11	MALIG.EPITHELIAL/MELANOMA													
11a	Adrenocortical carcinoma													
11b	Thyroid carcinoma													
11c	Nasopharyngeal carcinoma													
11d	Malignant melanoma													
11e	Skin carcinoma													
11f	Oth./unspec.carcinoma													
12	OTHER/UNSPEC.MALIG.NEOPLASM		1	1	2	5%	100%	14.7	12	9.2	8.2			
12a	Other spec. malignant													
12b	Other unspec. malignant		1	1	2	5%	100%	14.7	12	9.2	8.2			
	Total	2	8	13	15	38	100%	-	142.7	150.7	190.5	180.6	174	171.6

From 01/01/2006
 To 31/12/2008

International Classification for Childhood Cancer

Female		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					
		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude	ASR
1	LEUKAEMIA, MYELOPRO/MYELODYS.DIS.		4	2	3	9	0.31	1	80.2	30.9	38.1		43.6	45.8
01a	Lymphoid leukaemia		3	1	3	7	0.241	0.778	60.2	15.4	38.1		33.9	34.7
01b	Acute myeloid leukaemia		1	1		2	0.069	0.222	20.1	15.4			9.7	11.2
01c	Chronic myeloproliferative													
01d	Myelodysplas syn, myeloprolif.													
01e	Other/unspec leukaemia													
2	LYMPHOMAS, RETICULOENDOTHELIAL			1	3	4	0.138	1		15.4	38.1		19.4	16
02a	Hodgkin lymphoma				2	2	0.069	0.5			25.4		9.7	7.4
02b	NHL (not Burkitt)			1	1	2	0.069	0.5		15.4	12.7		9.7	8.7
02c	Burkitt lymphoma													
02d	Misc lymphoreticular													
02e	Unspecified lymphoma													
3	CNS, INTRACRANIAL/SPINAL	1	2		1	4	0.138	1	76.8	40.1	12.7		19.4	22
03a	Ependymoma, choroid plexus													
03b	Astrocytoma													
03c	Intracranial/spinal embryonal													
03d	Other glioma		1			1	0.034	0.25		20.1			4.8	6.2
03e	Oth.spec.intracranial/spinal													
03f	Unspec.intracranial/spinal	1	1		1	3	0.103	0.75	76.8	20.1	12.7		14.5	15.8
4	NEUROBLASTOMA, PER.NERV.CELL	2	2			4	0.138	1	153.6	40.1			19.4	24.3
04a	Neuro/ganglioneuroblastoma	2	2			4	0.138	1	153.6	40.1			19.4	24.3
04b	Other periph.nervous cell													
5	RETINOBLASTOMA													
6	RENAL TUMOUR													
06a	Nephroblastoma, non-epithel.renal													
06b	Renal carcinomas													
06c	Unspec.malig.renal													

7	HEPATIC TUMOUR					-								
07a	Hepatoblastoma													
07b	Hepatic carcinoma													
07c	Unspec.malig.hepatic													
8	MALIGNANT BONE TUMOUR		1	1		0.034	1		12.7	4.8	3.7			
08a	Osteosarcoma		1	1		0.034	1		12.7	4.8	3.7			
08b	Chondrosarcoma													
08c	Ewing, related bone sarcoma													
08d	Other spec. malig. bone													
08e	Unspec. malig. bone													
9	SOFT TISSUE, EXTRAOSS.SARCOMA													
09a	Rhabdomyosarcoma													
09b	Fibrosarc,periph.nerve sheath													
09c	Kaposi sarcoma													
09d	Oth.spec.soft tissue sarcoma													
09e	Unspec.soft tissue sarcoma													
10	GERM CELL,TROPHOBLAST,GONAD													
10a	Intracranial/spinal germ cell													
10b	Malig.extracran/gonad germ cell													
10c	Malignant gonadal germ cell													
10d	Gonadal carcinomas													
10e	Other malignant gonadal													
11	MALIG.EPITHELIAL/MELANOMA		5	5		0.172	1		63.4	24.2	18.4			
11a	Adrenocortical carcinoma													
11b	Thyroid carcinoma		4	4		0.138	0.8		50.7	19.4	14.7			
11c	Nasopharyngeal carcinoma													
11d	Malignant melanoma													
11e	Skin carcinoma													
11f	Oth./unspec.carcinoma		1	1		0.034	0.2		12.7	4.8	3.7			
12	OTHER/UNSPEC.MALIG.NEOPLASM	1	1	2		0.069	1	76.8	20.1	9.7	12.2			
12a	Other spec. malignant		1	1		0.034	0.5		20.1	4.8	6.2			
12b	Other unspec. malignant	1		1		0.034	0.5	76.8		4.8	5.9			
	Total	4	9	3	13	29	1	-	307.2	180.5	46.3	164.9	140.4	142.5

MECC JOINT REGISTRATION PROJECT

Cyprus Cancer Registry (CyCR)

Progress Report for 2011

(Data 2006-2008)